Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
Yuri Khodjamirian, fund manager at Tema ETFs, says there's a "valuation opportunity" in biotech stocks at the moment — but also warned of risks.
Yuri Khodjamirian, fund manager at Tema ETFs, says there's a "valuation opportunity" in biotech stocks at the moment — but also warned of risks.
